Sun Pharma & ICGEB sign exclusive deal on dengue vaccine — ARTES adds experience in VLP development and production

NEW DELHI, India I Octo­ber 19, 2016 

Inter­na­tion­al Cen­tre for Genet­ic Engi­neer­ing and Biotech­nol­o­gy (ICGEB) and Sun Phar­ma today announced their new col­lab­o­ra­tion for devel­op­ment of a dengue vac­cine, tar­get­ed against all the four serotypes of Dengue virus that cause dis­ease in humans. ICGEB has devel­oped a tai­lored recom­bi­nant virus-like-par­ti­cle (VLP) based tetrava­lent dengue vac­cine, con­tain­ing host-recep­tor bind­ing domain of enve­lope pro­tein of all the four DENV serotypes. ICGEB has con­duct­ed pre-clin­i­cal stud­ies over the past sev­en years and devel­oped the exist­ing Know-How and Patents for this dengue vac­cine candidate.

Sun Phar­ma invests over US$ 300 mil­lion annu­al­ly on research and devel­op­ment in phar­ma­ceu­ti­cals and bio­log­ics. The Com­pa­ny will use its in-house exper­tise as well as exper­tise of its Asso­ciate com­pa­ny, ARTES Biotech­nol­o­gy GmbH, in devel­op­ment of dengue vac­cine. ARTES will add their expe­ri­ence and pro­pri­etary know-how in pro­duc­tion of VLP based vac­cines from yeast pro­duc­tion cell lines. Hep‑B and HPV vac­cines devel­oped by ARTES are licensed to sev­er­al com­pa­nies world­wide and a Malar­ia vac­cine pro­gram is spon­sored by PATH (Malar­ia Vac­cine Ini­tia­tive). Tak­en togeth­er, the Com­pa­ny has past expe­ri­ence in devel­op­ment of Hep‑B and Typhoid vac­cines, as well as com­plex vac­cines, such as HPV and Malaria.


For the full text, see: